NASDAQ:PGNX
Delisted

Progenics Pharmaceuticals Inc. Stock Insider Trading

$4.10
+0 (+0%)
At Close: Sep 04, 2020
Date Action Amount Person Type
Jun 19, 2020 Sell 82 214 Das Asha Stock Option (Right to Buy)
Jun 19, 2020 Sell 125 000 Das Asha Stock Option (Right to Buy)
Jun 19, 2020 Sell 50 000 Ber Gerard Common Stock
Jun 19, 2020 Sell 16 393 Ber Gerard Stock Option (Right to Buy)
Jun 19, 2020 Sell 25 000 Campbell Bradley L Stock Option (Right to Buy)
Jun 19, 2020 Sell 20 000 Campbell Bradley L Stock Option (Right to Buy)
Jun 19, 2020 Sell 12 000 Campbell Bradley L Common Stock
Jun 19, 2020 Sell 28 000 Campbell Bradley L Stock Option (Right to Buy)
Jun 19, 2020 Sell 25 000 Campbell Bradley L Stock Option (Right to Buy)
Jun 19, 2020 Sell 16 393 Ende Eric J Stock Option (Right to Buy)
Jun 19, 2020 Sell 25 000 Ferrante Karen Jean Stock Option (Right to Buy)
Jun 19, 2020 Sell 40 000 Ferrante Karen Jean Stock Option (Right to Buy)
Jun 19, 2020 Sell 20 000 Ferrante Karen Jean Stock Option (Right to Buy)
Jun 19, 2020 Sell 20 000 Ferrante Karen Jean Stock Option (Right to Buy)
Jun 19, 2020 Sell 20 000 Ferrante Karen Jean Stock Option (Right to Buy)
Jun 19, 2020 Sell 20 000 Ferrante Karen Jean Stock Option (Right to Buy)
Jun 19, 2020 Sell 25 000 Ferrante Karen Jean Stock Option (Right to Buy)
Jun 19, 2020 Sell 36 065 Macdougall Ann L. Stock Option (Right to Buy)
Mar 02, 2020 Buy 82 214 Das Asha Non-Qualified Stock Option (Right to Buy)
Dec 13, 2019 Buy 36 065 Macdougall Ann L. Non-Qualified Stock Option (Right to Buy)
Dec 13, 2019 Buy 40 000 Macdougall Ann L. Non-Qualified Stock Option (Right to Buy)
Dec 13, 2019 Buy 16 393 Ende Eric J Non-Qualified Stock Option (Right to Buy)
Dec 13, 2019 Buy 40 000 Ende Eric J Non-Qualified Stock Option (Right to Buy)
Dec 13, 2019 Buy 16 393 Ber Gerard Non-Qualified Stock Option (Right to Buy)
Dec 13, 2019 Buy 40 000 Ber Gerard Non-Qualified Stock Option (Right to Buy)
Sep 18, 2019 Buy 0 Macdougall Ann L. Common Stock, $0.0013 par value
Sep 18, 2019 Buy 0 Ende Eric J Common Stock, $0.0013 par value
Sep 18, 2019 Buy 0 Ber Gerard Common Stock, $0.0013 par value
Sep 09, 2019 Buy 72 023 Velan Capital, L.p. Common Stock, $0.0013 par value
Sep 04, 2019 Buy 243 614 Velan Capital, L.p. Common Stock, $0.0013 par value
Sep 03, 2019 Buy 277 424 Velan Capital, L.p. Common Stock, $0.0013 par value
Aug 26, 2019 Buy 73 230 Velan Capital, L.p. Common Stock, $0.0013 par value
Aug 23, 2019 Buy 130 826 Velan Capital, L.p. Common Stock, $0.0013 par value
Aug 22, 2019 Buy 0 Velan Capital, L.p. Common Stock, $0.0013 par value
Jul 11, 2019 Buy 25 000 Scheinberg David A Non-Qualified Stock Option (Right to Buy)
Jul 11, 2019 Buy 25 000 Kishbauch Michael D Non-Qualified Stock Option (Right to Buy)
Jul 11, 2019 Buy 25 000 Ferrante Karen Jean Non-Qualified Stock Option (Right to Buy)
Jul 11, 2019 Buy 25 000 Campbell Bradley L Non-Qualified Stock Option (Right to Buy)
Jul 03, 2019 Buy 12 000 Campbell Bradley L Common Stock
Jul 03, 2019 Sell 12 000 Campbell Bradley L Non-Qualified Stock Option (Right to Buy)
Jul 01, 2019 Buy 10 000 Scheinberg David A Common Stock
Jul 01, 2019 Sell 10 000 Scheinberg David A Non-Qualified Stock Option (Right to Buy)
Feb 01, 2019 Buy 125 000 Das Asha Non-Qualified Stock Option (Right to Buy)
Jan 02, 2019 Buy 0 Das Asha Common Stock
Jun 13, 2018 Buy 25 000 Scheinberg David A Non-Qualified Stock Option (Right to Buy)
Jun 13, 2018 Buy 25 000 Kishbauch Michael D Non-Qualified Stock Option (Right to Buy)
Jun 13, 2018 Buy 25 000 Ferrante Karen Jean Non-Qualified Stock Option (Right to Buy)
Jun 13, 2018 Buy 25 000 Campbell Bradley L Non-Qualified Stock Option (Right to Buy)
Jun 14, 2017 Buy 20 000 Campbell Bradley L Non-Qualified Stock Option (Right to Buy)
Jun 14, 2017 Buy 20 000 Ferrante Karen Jean Non-Qualified Stock Option (Right to Buy)
Jun 14, 2017 Buy 20 000 Scheinberg David A Non-Qualified Stock Option (Right to Buy)
Jun 14, 2017 Buy 20 000 Kishbauch Michael D Non-Qualified Stock Option (Right to Buy)
Feb 15, 2017 Sell 150 000 Broadfin Healthcare Master Fund Ltd Common Stock
Feb 14, 2017 Sell 52 600 Broadfin Healthcare Master Fund Ltd Common Stock
Feb 14, 2017 Sell 50 000 Broadfin Healthcare Master Fund Ltd Common Stock
Feb 14, 2017 Sell 100 000 Broadfin Healthcare Master Fund Ltd Common Stock
Feb 14, 2017 Sell 150 000 Broadfin Healthcare Master Fund Ltd Common Stock
Feb 13, 2017 Sell 100 000 Broadfin Healthcare Master Fund Ltd Common Stock
Feb 09, 2017 Sell 100 000 Broadfin Healthcare Master Fund Ltd Common Stock
Feb 09, 2017 Sell 100 000 Broadfin Healthcare Master Fund Ltd Common Stock
Feb 09, 2017 Sell 1 300 Broadfin Healthcare Master Fund Ltd Common Stock
Feb 07, 2017 Sell 100 000 Broadfin Healthcare Master Fund Ltd Common Stock
Feb 07, 2017 Sell 50 000 Broadfin Healthcare Master Fund Ltd Common Stock
Jan 11, 2017 Sell 1 000 000 Broadfin Healthcare Master Fund Ltd Common Stock
Jun 08, 2016 Buy 20 000 Scheinberg David A Non-Qualified Stock Option (Right to Buy)
Jun 08, 2016 Buy 40 000 Campbell Bradley L Non-Qualified Stock Option (Right to Buy)
Jun 08, 2016 Buy 20 000 Ferrante Karen Jean Non-Qualified Stock Option (Right to Buy)
Jun 08, 2016 Buy 20 000 Kishbauch Michael D Non-Qualified Stock Option (Right to Buy)
Jun 08, 2016 Buy 0 Campbell Bradley L
Mar 01, 2016 Buy 82 500 Hirt Sheldon Non-Qualified Stock Option (right to buy)
Aug 03, 2015 Buy 125 000 Hirt Sheldon Non-Qualified Stock Option (right to buy)
Jul 06, 2015 Buy 0 Hirt Sheldon
Jun 10, 2015 Buy 20 000 Scheinberg David A Non-Qualified Stock Option (right to buy)
Jun 10, 2015 Buy 20 000 Kishbauch Michael D Non-Qualified Stock Option (right to buy)
Jun 10, 2015 Buy 20 000 Ferrante Karen Jean Non-Qualified Stock Option (right to buy)
Mar 02, 2015 Buy 15 342 Kishbauch Michael D Non-Qualified Stock Option (right to buy)
Jul 21, 2014 Buy 388 659 Broadfin Healthcare Master Fund Ltd Common Stock
Jul 18, 2014 Buy 388 200 Broadfin Healthcare Master Fund Ltd Common Stock
Jul 17, 2014 Buy 436 884 Broadfin Healthcare Master Fund Ltd Common Stock
Jul 16, 2014 Buy 411 693 Broadfin Healthcare Master Fund Ltd Common Stock
Jul 15, 2014 Buy 0 Broadfin Healthcare Master Fund Ltd Common Stock
Jun 17, 2014 Buy 20 000 Ferrante Karen Jean Non-Qualified Stock Option (right to buy)
Jun 17, 2014 Buy 20 000 Scheinberg David A Non-Qualified Stock Option (right to buy)
Jun 17, 2014 Buy 20 000 Kishbauch Michael D Non-Qualified Stock Option (right to buy)
Jan 29, 2014 Buy 40 000 Ferrante Karen Jean Non-Qualified Stock Option (right to buy)
Jan 29, 2014 Buy 0 Ferrante Karen Jean
Sep 11, 2013 Buy 40 000 Kishbauch Michael D Non-Qualified Stock Option (right to buy)
Sep 11, 2013 Buy 0 Kishbauch Michael D
Jun 12, 2013 Buy 20 000 Scheinberg David A Non-Qualified Stock Option (right to buy)
Mar 22, 2013 Buy 1 250 Scheinberg David A Common Stock
Mar 22, 2013 Sell 1 250 Scheinberg David A Common Stock
Mar 21, 2013 Buy 1 250 Scheinberg David A Non-Qualified Stock Option (right to buy)
Jun 13, 2012 Buy 10 000 Baker Charles A Non-Qualified Stock Option (right to buy)
Jun 13, 2012 Buy 10 000 Briner Kurt W Non-Qualified Stock Option (right to buy)
Jun 13, 2012 Buy 10 000 Scheinberg David A Non-Qualified Stock Option (right to buy)
Feb 23, 2012 Buy 1 250 Scheinberg David A Common Stock
Feb 23, 2012 Sell 1 250 Scheinberg David A Common Stock
Feb 23, 2012 Buy 1 250 Scheinberg David A Non-Qualified Stock Option (right to buy)
Feb 23, 2012 Sell 1 250 Scheinberg David A Non-Qualified Stock Option (right to buy)
Feb 03, 2012 Sell 33 000 Briner Kurt W Common Stock
INSIDER POWER
0
Last 100 transactions
Buy: 3 698 460 | Sell: 2 618 715 (Shares)

Based on the 100 latest insides trades, we have calculated the insider power to be negative at a ratio of 0.000.

In total, the insiders bought 3 698 460 and sold 2 618 715 PGNX shares in the last 100 trades.

Click to get the best stock tips daily for free!

About Progenics Pharmaceuticals Inc.

Progenics Pharmaceuticals. Progenics Pharmaceuticals, Inc. develops medicines for oncology in the United States and internationally. The company’s primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule that has completed Phase II testing, as well as acts as an ... PGNX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT